세계의 강직성 척추염 시장 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2030년)

The global demand for Ankylosing Spondylitis Market is presumed to reach the market size of nearly USD 10.85 BN by 2030 from USD 5.29 BN in 2022 with a CAGR of 9.4% under the study period 2023 - 2030.

Ankylosing spondylitis (AS) is a persistent autoimmune condition that predominantly targets the spine and sacroiliac joints, but it can also impact other joints and organs. It belongs to the category of spondyloarthritis, a cluster of disorders characterized by joint and enthesis inflammation (the locations where ligaments and tendons attach to bones).

MARKET DYNAMICS:

Increased awareness of ankylosing spondylitis, improved diagnostic methods, and advancements in treatment options, particularly biologic therapies and disease-modifying drugs, are driving the market. The aging global population contributes to a greater number of individuals at risk of this condition, further increasing demand for ankylosing spondylitis-related healthcare services. Genetic research and emerging markets are expanding the market's reach. Regulatory support, patient-centric care, and digital health solutions are also propelling the ankylosing spondylitis market forward. Ongoing research and clinical trials promise new treatment modalities and therapies, fostering continued innovation in its management.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of ankylosing spondylitis. The growth and trends of ankylosing spondylitis industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the ankylosing spondylitis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug

• Cosentyx
• Humira
• Simponi
• Remicade
• Enbrel
• Cimzia
• Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Ankylosing Spondylitis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Ankylosing Spondylitis market include AbbVie, Inc., Amgen, Inc., Pfizer, Inc., Novartis AG, Eli Lilly and Company, UCB, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . ANKYLOSING SPONDYLITIS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug
  • 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ANKYLOSING SPONDYLITIS MARKET ANALYSIS BY DRUG

• 5.1 Overview by Drug
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug
• 5.4 Cosentyx Historic and Forecast Sales by Regions
• 5.5 Humira Historic and Forecast Sales by Regions
• 5.6 Simponi Historic and Forecast Sales by Regions
• 5.7 Remicade Historic and Forecast Sales by Regions
• 5.8 Enbrel Historic and Forecast Sales by Regions
• 5.9 Cimzia Historic and Forecast Sales by Regions
• 5.10. Others Historic and Forecast Sales by Regions

6 . GLOBAL ANKYLOSING SPONDYLITIS MARKET ANALYSIS BY GEOGRAPHY

• 6.1. Regional Outlook
• 6.2. Introduction
• 6.3. North America Sales Analysis
  • 6.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.3.2. North America By Segment Sales Analysis
  • 6.3.3. North America By Country Sales Analysis
  • 6.3.4. United State Sales Analysis
  • 6.3.5. Canada Sales Analysis
  • 6.3.6. Mexico Sales Analysis
• 6.4. Europe Sales Analysis
  • 6.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.4.2. Europe by Segment Sales Analysis
  • 6.4.3. Europe by Country Sales Analysis
  • 6.4.4. United Kingdom Sales Analysis
  • 6.4.5. France Sales Analysis
  • 6.4.6. Germany Sales Analysis
  • 6.4.7. Italy Sales Analysis
  • 6.4.8. Russia Sales Analysis
  • 6.4.9. Rest Of Europe Sales Analysis
• 6.5. Asia Pacific Sales Analysis
  • 6.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.5.2. Asia Pacific by Segment Sales Analysis
  • 6.5.3. Asia Pacific by Country Sales Analysis
  • 6.5.4. China Sales Analysis
  • 6.5.5. India Sales Analysis
  • 6.5.6. Japan Sales Analysis
  • 6.5.7. South Korea Sales Analysis
  • 6.5.8. Australia Sales Analysis
  • 6.5.9. South East Asia Sales Analysis
  • 6.5.10. Rest Of Asia Pacific Sales Analysis
• 6.6. Latin America Sales Analysis
  • 6.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.6.2. Latin America by Segment Sales Analysis
  • 6.6.3. Latin America by Country Sales Analysis
  • 6.6.4. Brazil Sales Analysis
  • 6.6.5. Argentina Sales Analysis
  • 6.6.6. Peru Sales Analysis
  • 6.6.7. Chile Sales Analysis
  • 6.6.8. Rest of Latin America Sales Analysis
• 6.7. Middle East & Africa Sales Analysis
  • 6.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 6.7.2. Middle East & Africa by Segment Sales Analysis
  • 6.7.3. Middle East & Africa by Country Sales Analysis
  • 6.7.4. Saudi Arabia Sales Analysis
  • 6.7.5. UAE Sales Analysis
  • 6.7.6. Israel Sales Analysis
  • 6.7.7. South Africa Sales Analysis
  • 6.7.8. Rest Of Middle East And Africa Sales Analysis

7 . COMPETITIVE LANDSCAPE OF THE ANKYLOSING SPONDYLITIS COMPANIES

• 7.1. Ankylosing Spondylitis Market Competition
• 7.2. Partnership/Collaboration/Agreement
• 7.3. Merger And Acquisitions
• 7.4. New Product Launch
• 7.5. Other Developments

8 . COMPANY PROFILES OF ANKYLOSING SPONDYLITIS INDUSTRY

• 8.1. Company Share Analysis
• 8.2. Market Concentration Rate
• 8.3. AbbVie, Inc.
  • 8.3.1. Company Overview
  • 8.3.2. Company Revenue
  • 8.3.3. Products
  • 8.3.4. Recent Developments
• 8.4. Amgen, Inc.
  • 8.4.1. Company Overview
  • 8.4.2. Company Revenue
  • 8.4.3. Products
  • 8.4.4. Recent Developments
• 8.5. Pfizer, Inc.
  • 8.5.1. Company Overview
  • 8.5.2. Company Revenue
  • 8.5.3. Products
  • 8.5.4. Recent Developments
• 8.6. Novartis AG
  • 8.6.1. Company Overview
  • 8.6.2. Company Revenue
  • 8.6.3. Products
  • 8.6.4. Recent Developments
• 8.7. Eli Lilly and Company
  • 8.7.1. Company Overview
  • 8.7.2. Company Revenue
  • 8.7.3. Products
  • 8.7.4. Recent Developments
• 8.8. UCB, Inc.
  • 8.8.1. Company Overview
  • 8.8.2. Company Revenue
  • 8.8.3. Products
  • 8.8.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies